中国生物科技服务(08037)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

08037 中国生物科技服务

未开盘 09-11 14:53:44

0.610

-0.005

-0.81%

最高0.620	最低0.585	成交量9.00万
今开0.615	昨收0.615	日振幅5.69%
总市值5.95亿	流通市值5.95亿	总股本9.76亿
成交额5.54万	换手率0.01%	流通股本9.76亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"08037","market":"HK","secType":"STK","nameCN":"中国生物科技服务","latestPrice":0.61,"timestamp":1789109624194,"preClose":0.615,"halted":0,"volume":90000,"delay":0,"changeRate":-0.008130081300813016,"floatShares":975731150,"shares":975731150,"eps":-0.070488,"marketStatus":"未开盘","change":-0.005,"latestTime":"09-11 14:53:44","open":0.615,"high":0.62,"low":0.585,"amount":55350,"amplitude":0.056911,"askPrice":0.62,"askSize":10000,"bidPrice":0.595,"bidSize":5000,"shortable":0,"etf":0,"ttmEps":-0.019003,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"listingDate":1087401600000,"exchange":"SEHK","adjPreClose":0.615,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"volumeRatio":1.20000000144,"lotSize":5000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/08037","defaultTab":"news","newsList":[{"id":"2664297844","title":"中国生物科技服务(08037)：鹏博(海南)硼中子医院与天马医疗成员机构安康订立合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2664297844","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664297844?lang=zh_cn&edition=full","pubTime":"2026-09-03 06:37","pubTimestamp":1788388647,"startTime":"0","endTime":"0","summary":"合作协议为框架协议，自签署之日起计为期一年，经协商可予续期。安康为中国香港一所综合肿瘤专科机构。集团先前已与内地知名医院如北京和睦家医院管理有限公司签署合作协议，借此拓展中国市场的患者来源。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1511","08037","159891","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1165476210","title":"中国生物科技服务（08037）旗下硼中子医院与安康签署跨境肿瘤合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1165476210","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1165476210?lang=zh_cn&edition=full","pubTime":"2026-09-03 06:11","pubTimestamp":1788387083,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司9月2日公告，其附属公司鹏博（海南）硼中子医疗科技有限公司已与天马医疗集团成员机构——香港综合肿瘤专科机构安康医疗癌症中心签署为期一年的框架合作协议，协议期满可协商续期。中国生物科技服务此前已与北京和睦家医院管理有限公司等内地医疗机构签署合作协议，以拓展中国市场患者来源。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159597138","title":"中国生物科技服务控股有限公司签署跨境BNCT临床服务合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1159597138","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159597138?lang=zh_cn&edition=full","pubTime":"2026-09-03 06:07","pubTimestamp":1788386829,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司（股份代号：08037）近日宣布，已就跨境硼中子俘获治疗（BNCT）临床服务相关事宜正式达成一项合作协议。\n据了解，此次合作聚焦于推动BNCT这一前沿抗癌技术在不同司法管辖区之间的临床应用与患者服务对接。通过该协议的签署，公司旨在进一步拓展其肿瘤治疗服务网络，并加强与国际医疗机构的协作深度。\n协议的具体条款显示，双方将整合各自在技术、资源及临床实践方面的优势，共同探索跨境医疗服务的标准化路径。此举不仅有望提升BNCT技术的可及性，也为后续更广泛的国际医疗合作奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1511","08037","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154336437","title":"中国生物科技服务旗下鹏博（海南）博鳌医院与Oncocare签署合作协议（2026年9月2日）","url":"https://stock-news.laohu8.com/highlight/detail?id=1154336437","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154336437?lang=zh_cn&edition=full","pubTime":"2026-09-03 06:07","pubTimestamp":1788386829,"startTime":"0","endTime":"0","summary":"中国生物科技服务（08037.HK）旗下鹏博（海南）博鳌医院，于2026年9月2日与Oncocare正式达成战略合作协议。此次携手，标志着双方在相关医疗领域的深度合作正式启航。协议的签署，无疑将为未来的业务拓展与技术创新注入新的活力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037","BK1511","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162724352","title":"中国生物科技服务8月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1162724352","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162724352?lang=zh_cn&edition=full","pubTime":"2026-09-01 21:01","pubTimestamp":1788267702,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司于2026年9月1日发布截至2026年8月31日止的最新股份变动月报。公告显示，报告期内公司法定及已发行股本总体保持稳定，未发生新增发行、回购或注销行为。本期法定注册股本维持在2,000,000,000股，面值每股0.1港元，对应法定注册股本2.00亿港元，与上期相比无变化。目前上述可换股票据发行规模保持不变，报告期内无新增转换。本月末公司总股本保持在975,731,150股，整体股本结构未发生变化。该公告由执行董事刘小林签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663090448","title":"中国生物科技服务(08037)发布中期业绩，股东应占溢利1823万港元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2663090448","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663090448?lang=zh_cn&edition=full","pubTime":"2026-08-29 01:20","pubTimestamp":1787937626,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物科技服务(08037)发布截至2026年6月30日止6个月的中期业绩，该集团取得收入3722.6万港元，同比增加49.71%;本公司拥有人应占溢利1823万港元，同比扭亏为盈;每股盈利0.03港元。公告称，收入增加主要由鹏博(海南)硼中子医院(硼中子俘获治疗中心)自2026年2月起开始试营运所驱动，以及来自提供硼中子俘获治疗服务的收入约为2670万港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1488867.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1219","08037","BK1511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105270972","title":"中国生物科技服务2026年上半年营收0.37亿港元，经调整净利润0.18亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1105270972","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105270972?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:41","pubTimestamp":1787928103,"startTime":"0","endTime":"0","summary":"2026年上半年，中国生物科技服务实现营收约3,722.60万港元，较上年同期的2,486.50万港元增长约49.70%。经调整净利润约为1,823.00万港元，相比上年同期约3,200万港元的亏损，成功实现扭亏为盈。业务分项方面，硼中子俘获治疗业务自2026年2月开展试运营后，贡献了约2,671.50万港元收入。公司表示将持续实施肿瘤免疫细胞治疗和硼中子俘获治疗两大核心业务的发展策略，致力于在先进癌症治疗领域保持优势地位，未来将继续推动技术创新和业务规模化进程。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"中国生物科技服务2026年上半年营收0.37亿港元，经调整净利润0.18亿港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154163921","title":"中国生物科技服务控股有限公司——董事会决议不就截至2026年6月30日止期间宣派任何股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1154163921","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154163921?lang=zh_cn&edition=full","pubTime":"2026-08-28 22:38","pubTimestamp":1787927910,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司于近日宣布，公司董事会已正式决定，针对截至2026年6月30日止的财年期间，将不宣派任何股息。此项决议意味着，在该报告期内，股东将不会获得现金分红或其他形式的利润分配。董事会的这一决定，无疑是对当前财务状况和未来资金需求进行审慎考量后的结果。对于投资者而言，这一消息无疑需要纳入其投资决策的重要考量因素之中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037","BK1219","BK1511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659150458","title":"中国生物科技服务(08037.HK)完成出售标准病理检验所及卓纪保健的全部已发行股本","url":"https://stock-news.laohu8.com/highlight/detail?id=2659150458","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659150458?lang=zh_cn&edition=full","pubTime":"2026-08-13 21:42","pubTimestamp":1786628575,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1219","08037","BK1511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159927325","title":"中国生物科技服务（08037）完成出售香港实验室检测业务  聚焦硼中子俘获治疗产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=1159927325","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159927325?lang=zh_cn&edition=full","pubTime":"2026-08-13 21:36","pubTimestamp":1786628164,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司8月13日公告，公司已于同日完成出售标准病理检验所有限公司及卓纪保健有限公司全部已发行股本的主要交易。公告显示，买卖协议所载的所有先决条件均已满足，交易正式交割后，上述两家公司不再为中国生物科技服务附属公司，其财务业绩亦将不再并入集团合并报表。公司表示，此次剥离持续亏损的香港实验室检测业务，是落实业务战略转型的重要一环。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659184539","title":"中国生物科技服务预计2026年中期净利润不少于1500万港元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2659184539","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659184539?lang=zh_cn&edition=full","pubTime":"2026-08-13 08:59","pubTimestamp":1786582740,"startTime":"0","endTime":"0","summary":"8月12日，中国生物科技服务（08037）发布公告，预计在截至2026年6月30日的6个月内，集团将录得不少于1500万港元的净利润，而在截至2025年6月30日的同期则为约3700万港元的净亏损。预计由亏损净额转为盈利的主要原因是可转换债券可能出现的非现金及未变现公平值收益介于7700万港元至8700万港元之间。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608133839948859.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608133839948859.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903756","title":"中国生物科技服务(08037.HK)发盈喜 预计上半年溢利净额不少于1500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903756","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658903756?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:16","pubTimestamp":1786544180,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["08037","BK1219","BK1511"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167031144","title":"中国生物科技服务（08037）定于8月28日审议截至6月30日止半年业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1167031144","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167031144?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:15","pubTimestamp":1786544141,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司（股票代码：08037）8月12日公告称，公司董事会已决定于2026年8月28日（星期五）召开会议，审议并批准公司及其附属公司截至2026年6月30日止六个月的未经审计简明综合中期业绩，并讨论派发股息事宜（如有）。\n公告披露，董事会目前由六名董事组成，包括三名执行董事刘小林先生（主席）、黄嵩博士及尹燁博士，以及三名独立非执行董事鄢国祥先生、郭圆濤博士和张晓博士。\n根据公告，该文件已按照香港联交所GEM上市规则发布，自刊登之日起将在联交所网站及公司官网分别公开至少七天。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167667219","title":"中国生物科技服务（08037）发盈利预告：2026财年中期预计净赚不少于1,500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167667219","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167667219?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:10","pubTimestamp":1786543828,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司8月12日公告，根据对集团截至2026年6月30日止六个月的未经审核综合管理账目之初步评估，公司预计将录得不少于1,500万港元的溢利净额；而上年同期则录得约3,700万港元的亏损净额，实现由亏转盈。公司表示，相关数据基于管理层初步审阅结果，未经审核委员会审阅，最终中期业绩预计将于2026年8月底公布。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153510377","title":"中国生物科技服务预期中期净利润主要来自可换股债券公允价值收益，金额约7700万至8700万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1153510377","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153510377?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:09","pubTimestamp":1786543749,"startTime":"0","endTime":"0","summary":"中国生物科技服务（08037.HK）预期，其中期净利润将主要来自一笔可换股债券的公允价值收益。该收益规模预计在7700万至8700万港元之间。公司强调，这笔非现金性质的收益，成为推动本期业绩实现盈利的关键因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1511","08037","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190494426","title":"中国生物科技服务预期2026年上半年净利润不低于1500万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1190494426","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190494426?lang=zh_cn&edition=full","pubTime":"2026-08-12 22:09","pubTimestamp":1786543749,"startTime":"0","endTime":"0","summary":"中国生物科技服务（CH BIOTECH SER）发布公告，预期截至2026年6月30日止六个月内，公司将录得净利润不少于1500万港元。这一业绩预期反映出公司在生物科技领域的持续增长动力。值得注意的是，相较于去年同期，这一盈利指引标志着公司经营状况的显著改善。市场分析人士认为，这主要得益于公司在生物医药研发及服务板块的强劲表现。具体财务数据将于中期业绩报告中正式披露，届时投资者可进一步审视公司的盈利质量与现金流状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1219","BK1511","08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658928935","title":"中国生物科技服务(08037.HK)构建BNCT“药-械-医”全闭环 产业模式全面升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2658928935","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658928935?lang=zh_cn&edition=full","pubTime":"2026-08-12 11:25","pubTimestamp":1786505111,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1511","08037","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658944957","title":"中国生物科技服务称与Stella Pharma就硼中子治疗药物在中国商业化订立协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2658944957","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658944957?lang=zh_cn&edition=full","pubTime":"2026-08-12 08:25","pubTimestamp":1786494326,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1511","BK1219","08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161506734","title":"中国生物科技服务（08037）落实Steboronine®在华布局 与Stella Pharma签署10年独家商业化协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1161506734","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161506734?lang=zh_cn&edition=full","pubTime":"2026-08-12 08:20","pubTimestamp":1786494039,"startTime":"0","endTime":"0","summary":"中国生物科技服务控股有限公司8月12日发布自愿公告称，公司与STELLA PHARMA CORPORATION在2026年8月11日签订关于硼中子治疗药物Steboronine在中国开发及商业化的主合作协议。该合作基于双方于2025年5月8日签署的谅解备忘录，标志双方合作进入具法律约束力的新阶段。若Stella Pharma未能在签署日起10年内获得NMPA批准，协议将于期满自动终止。中国生物科技服务表示，与Stella Pharma的深入合作有望加速Steboronine在中国的研发和商业化进程，进一步夯实集团在硼中子治疗上游产业的布局。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["08037"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657017695","title":"中国生物科技服务(08037)：华大松禾投资已经完成 鹏博(海南)由华大松禾持有6.25%权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2657017695","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657017695?lang=zh_cn&edition=full","pubTime":"2026-08-07 12:19","pubTimestamp":1786076378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物科技服务(08037)发布公告，有关华大松禾投资的相关事宜。于补充协议内所载的所有先决条件均已经获履行，而华大松禾投资已经完成。于本公告日期，鹏博(海南)由华大松禾持有6.25%权益。鹏博(海南)将仍然为本公司的非全资附属公司，而鹏博(海南)的财务报表将会继续合并入本集团的财务报表。交易完成提升鹏博(海南)的企业形象及其资本基础。其标志着华大松禾对硼中子俘获治疗中心未来发展，以及本集团致力于为有需要的癌症患者提供硼中子俘获治疗服务的承诺的信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["08037","BK1219","BK1511"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ruikang.com.hk","stockEarnings":[{"period":"1week","weight":-0.0317},{"period":"1month","weight":-0.0615},{"period":"3month","weight":0.2979},{"period":"6month","weight":-0.1528},{"period":"1year","weight":-0.4299},{"period":"ytd","weight":-0.2278}],"compareEarnings":[{"period":"1week","weight":-0.033},{"period":"1month","weight":-0.0249},{"period":"3month","weight":0.0035},{"period":"6month","weight":-0.0259},{"period":"1year","weight":-0.0491},{"period":"ytd","weight":-0.0322}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"中国生物科技服务控股有限公司（原名：锐康药业集团投资有限公司）是一家主要从事提供医学检测服务的投资控股公司。该公司通过六个分部运营业务。医学及保健相关服务分部主要提供医学实验室检测服务及健康检查服务。保险经纪分部主要提供保险经纪服务。免疫治疗分部主要提供肿瘤免疫细胞治疗、免疫细胞存储及健康管理服务。医药产品分部主要制造、研发、销售及分销保健相关及医药产品。证券分部主要从事买卖证券业务。其他分部主要从事放债业务及提供物流服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.181818,"avgChangeRate":-0.029278},{"month":2,"riseRate":0.5,"avgChangeRate":0.10268},{"month":3,"riseRate":0.363636,"avgChangeRate":-0.059753},{"month":4,"riseRate":0.272727,"avgChangeRate":-0.012084},{"month":5,"riseRate":0.681818,"avgChangeRate":0.094181},{"month":6,"riseRate":0.409091,"avgChangeRate":-0.024587},{"month":7,"riseRate":0.391304,"avgChangeRate":-0.011934},{"month":8,"riseRate":0.304348,"avgChangeRate":0.00008},{"month":9,"riseRate":0.217391,"avgChangeRate":-0.036666},{"month":10,"riseRate":0.318182,"avgChangeRate":0.014648},{"month":11,"riseRate":0.454545,"avgChangeRate":0.045242},{"month":12,"riseRate":0.5,"avgChangeRate":-0.009269}],"exchange":"SEHK","name":"中国生物科技服务","nameEN":"CH BIOTECH SER"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国生物科技服务(08037)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国生物科技服务(08037)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国生物科技服务,08037,中国生物科技服务股票,中国生物科技服务股票老虎,中国生物科技服务股票老虎国际,中国生物科技服务行情,中国生物科技服务股票行情,中国生物科技服务股价,中国生物科技服务股市,中国生物科技服务股票价格,中国生物科技服务股票交易,中国生物科技服务股票购买,中国生物科技服务股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国生物科技服务(08037)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国生物科技服务(08037)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}